CN106581080B - Application of Phascolosoma esculenta in preparation of blood lipid lowering medicine and health product - Google Patents
Application of Phascolosoma esculenta in preparation of blood lipid lowering medicine and health product Download PDFInfo
- Publication number
- CN106581080B CN106581080B CN201611088037.XA CN201611088037A CN106581080B CN 106581080 B CN106581080 B CN 106581080B CN 201611088037 A CN201611088037 A CN 201611088037A CN 106581080 B CN106581080 B CN 106581080B
- Authority
- CN
- China
- Prior art keywords
- phascolosoma esculenta
- phascolosoma
- esculenta
- group
- liver
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/655—Aquatic animals other than those covered by groups A61K35/57 - A61K35/65
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Oceanography (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention discloses an application of Phascolosoma esculenta in preparing hypolipidemic drugs and health products, wherein the Phascolosoma esculenta is selected from natural Phascolosoma esculenta, washed away silt by clear water, washed clean by saline water for multiple times, sun-dried and naturally air-dried outdoors in daytime, dried in a drying oven at 28 ℃ at night until the weight is constant, and subjected to intermittent grinding and screening by a dry powder grinder to prepare Phascolosoma esculenta powder which is applied to hypolipidemic drugs and health products. The Phascolosoma esculenta powder can reduce the levels of serum Total Cholesterol (TC), Triglyceride (TG) and low-density lipoprotein cholesterol (LDL-C) of hyperlipidemia, increase the level of high-density lipoprotein cholesterol (HDL-C), and has a certain protective effect on liver. The phascolosoma esculenta belongs to natural food, has no toxic or side effect on human bodies, is rich in raw materials, simple in preparation process, free of chemical reagent addition in the preparation process, and has good industrial application prospect.
Description
[ technical field ] A method for producing a semiconductor device
The invention relates to the application field of phascolosoma esculenta, in particular to application of phascolosoma esculenta in preparing a blood fat reducing medicine and a blood fat reducing health-care product.
[ background of the invention ]
In recent years, the incidence of hyperlipidemia has been on an increasing trend with the improvement in living standards and the change in dietary structure. Research shows that hyperlipidemia is one of the main risk factors of atherosclerosis, so that a series of cardiovascular and cerebrovascular diseases which are harmful to human health, such as hypertension, coronary heart disease, myocardial infarction, cerebral apoplexy and the like, are caused, and become serious public health problems facing the world.
Modern medical research suggests that dyslipidemia is primarily manifested by elevated plasma or serum Total Cholesterol (TC), total Triglycerides (TG), low density lipoprotein cholesterol (LDL-C) levels and/or reduced high density lipoprotein cholesterol (HDL-C) levels. Although many chemical drugs are available to reduce serum cholesterol, they have various degrees of toxic side effects, such as gastrointestinal reactions, liver and kidney damage. Therefore, the search for natural active substances with high efficiency and low toxicity from nature for the prevention and treatment of related diseases has become a focus of medical attention in recent years.
The Phascolosoma esculenta (Phascolosoma esculenta) is commonly called as 'mashed garlic', sea maggot, sandworm, sarcandra, and bamboo shoot, belongs to the Astera (Sipuluodea) Astera (Sipulula) of the Astera phylum Sipulosum, is a special species in China, is distributed in intertidal zones and mud beaches of high-tide zones in Guangxi, Guangdong, Hainan, Fujian, Zhejiang and the like in the southeast of China, and has abundant yield. Phascolosoma esculenta is a high protein, low fat marine organism. The edible and medicinal values of various Chinese herbal medicines are recorded in China, the Chinese herbal medicines are traditional medical food nourishing good products in China, and the Chinese herbal medicines are used for replacing Chinese caterpillar fungus in some areas. The Phascolosoma esculenta is found to have the effects of resisting fatigue (Chinese patent CN102153666B) and septicemia (Chinese patent CN 103483462B).
The applicant finds that the phascolosoma esculenta has obvious effects of reducing blood fat and protecting the liver, and has no toxic or side effect of chemical hypolipidemic drugs.
[ summary of the invention ]
The invention discloses application of Phascolosoma esculenta powder which is rich in raw materials, simple in manufacturing process and free of chemical reagent addition in the manufacturing process in preparation of a blood fat reducing drug and a blood fat reducing health-care product.
The method comprises the following implementation steps:
1. raw materials: selecting natural high-quality phascolosoma esculenta;
2. cleaning: washing away silt by using clear water, and then washing by using salt water for multiple times;
3. air drying: sun drying and natural air drying outdoors in daytime;
4. drying: drying at 28 deg.C in a drying oven at night until constant weight;
5. grinding: intermittently grinding by a dry powder grinder;
6. grading and screening: sequentially sieving with 20 mesh, 40 mesh and 60 mesh sieves to obtain Phascolosoma esculenta dry powder;
the prepared Phascolosoma esculenta powder is applied to blood fat reducing medicines and blood fat reducing health care products.
The invention has the beneficial effects that: the Phascolosoma esculenta adopted by the invention belongs to natural food, and no chemical reagent is added in the processing process, so that the phascolosoma esculenta has no toxic or side effect on a user; the invention also has the advantages of abundant raw materials and simple manufacturing process, and has good industrial application prospect.
[ description of the drawings ]
FIG. 1 is a schematic process flow diagram of the present invention;
FIG. 2 is a graph of the change in weight of a mouse during the application of the present invention;
FIG. 3 is a graph of liver changes in mice;
FIG. 4 BCA assay standard curve for protein content
[ detailed description ] embodiments
The invention will be further described with reference to specific examples, but the scope of the invention is not limited thereto:
example 1: preparation of Phascolosoma esculenta dry powder
(1) Selecting raw materials: the Phascolosoma esculenta used in the invention is purchased from the Anhai town of Jinjiang city, Fujian province and is a natural sipunculus esculenta;
(2) cleaning: the cleaning process has a certain disinfection effect, and is good in effect and low in cost;
(3) air drying: sun drying and natural air drying outdoors in daytime;
(4) drying: drying at 28 deg.C in a drying oven at night until constant weight;
(5) grinding: intermittently grinding for multiple times by a dry powder grinder to form coarse sipunculus nudus powder;
(6) grading and screening: sieving with 20 mesh, 40 mesh and 60 mesh sieves in sequence to obtain fine powder of more than 60 meshes, namely the Phascolosoma esculenta dry powder.
The dry powder of the sipunculus nudus prepared by the method is characterized by no chemical additive in the process, no pollution, pure nature and environmental protection, and is used for the application of the sipunculus nudus in the later period.
Example 2: influence of Phascolosoma esculenta powder on blood lipid
1. Test materials and methods
1.1 Experimental materials: the male Kunming mouse is selected and purchased from Wu's animal center of Fuzhou university.
1.2 high fat feed formula (W/W): 78.8% of basal feed, 1% of cholesterol, 10% of egg yolk powder, 10% of lard oil and 0.2% of bile salt.
1.3 Main instruments and reagents
Analytical balance, oven, dry powder grinder, spectrophotometer, multifunctional microplate reader (TECAN, infiniteem 2000), bench centrifuge (XiangYi, H1650-W); the positive control 1 is a decoction-minister doubly-healthy soybean phospholipid soft capsule (decoction-minister doubly-healthy stock Co., Ltd., national food-healthy character G20070415); the positive control 2 is a lipid-lowering tablet (taiji group Chongqing Tongjun pharmaceutical factory, ltd., national drug standard Z50020125); triglyceride (TG) kit, Total Cholesterol (TC) kit, high density lipoprotein cholesterol (HDL-C) kit, and low density lipoprotein cholesterol (LDL-C) kit were purchased from Nanjing to build the bioengineering institute; the bicinchoninic acid (BCA) protein concentration determination kit is purchased from Biyuntian biotechnology limited; the other reagents are all chemical analytically pure and purchased from chemical reagents of national drug group, Inc.
1.4 Experimental methods:
(1) adapting to the environment: all animals are fed and observed by basic feed, the feeding temperature is 25 +/-2 ℃, and the environment is adapted for 7 days;
(2) and (3) random grouping: seven groups were randomized, 10 per group: the first group is a normal group, the second group is a negative control group, the third group is a positive control group 1 (a soybean phospholipid soft capsule is given), the fourth group is a positive control group 2 (a lipid lowering tablet is given), the fifth group is a low-dose administration group, the sixth group is a medium-dose administration group, and the seventh group is a high-dose administration group;
(3) molding high-fat feed: except for the normal group fed with the basal feed, other 6 groups of animals are changed into high-fat feed for experimental hyperlipidemia molding, fed for 30-35 days, and serum TC and TG levels are measured to determine the formation of hyperlipidemia; -
(4) Administration treatment: after molding is finished, the administration dose of the mice is converted according to 9 times of the administration dose of adults, the positive control group 1 is administered with 0.03g/kg (body mass) of soybean lecithin, the positive control group 2 is administered with 0.0625g/kg (body mass) of lipid-lowering tablets, the low dose administration group is administered with 0.675g/kg (body mass) of sipunculid dry powder physiological saline suspension, the middle dose group is administered with 1.35g/kg (body mass) of sipunculid dry powder physiological saline suspension, the high dose group is administered with 2.7g/kg (body mass) of sipunculid dry powder physiological saline suspension, and the negative control group is administered with the same volume of physiological saline and is continuously perfused for 25 days;
(5) obtaining and detecting mouse detection materials:
a. serum: after 25 days of administration, the experimental hyperlipidemic mice were fasted for 16h, and blood was sampled from the eyeball to examine serum indices including TG, TC, and HDL-C, LDL-C, and an arteriosclerosis index AI (AI ═ TC-HDL-C)/HDL-C was calculated.
b, liver: after an eyeball of a mouse is picked and blood is taken, cervical vertebra is dislocated and killed, a complete liver is picked, the whole liver is rinsed by normal saline and then is sucked by filter paper, the weight of the whole liver is weighed, the liver coefficient (%) ═ liver weight (g)/body weight (g) × 100) is calculated, the liver tissue of the mouse is taken, PBS buffer solution tissue is added according to the volume ratio of 1:9, and the protein concentration, TG and TC content of the liver tissue are measured after grinding and centrifugation.
(6) And (3) experimental data statistics: the test results were statistically analyzed using SPSS, and the results were expressed as mean ± standard deviation, and the groups were compared with each other using t-test. p <0.05 (. sup.) > indicates significant difference, and p <0.01 (. sup.) -indicates very significant difference.
2. Results
2.1 Effect on mouse body weight:
the body weight changes of mice before and after administration are shown in figure 2, and it is known from the figure that the weight average of the mice of each group is increased along with the increase of the feeding time, the increasing trend is similar to that of the normal group, the body weight growth rate of the mice of each group has no significant difference (P is more than 0.05), and the mice of each group grow well without adverse reaction.
2.2 Effect of Phascolosoma esculenta on the blood lipid levels of hyperlipidemic model mice
Table 1 mouse sera TG, TC, LDL-C, HDL-C and AI values (n-10,
)
(p <0.01 indicates a significant difference from the negative control group, and p <0.05 indicates a significant difference from the negative control group)
Table 1 is the effect of phascolosoma esculenta on the blood lipid levels of hyperlipidemic model mice: data results show that compared with a normal group, the serum contents of TG, TC and LDL-C in mice in a negative control group are obviously increased, and the HDL-C content is obviously reduced, which indicates that a hyperlipidemia model is successfully established. Compared with the negative control group, the content of TG, TC and LDL-C in the sipunculus administration group is reduced, and the content of HDL-C is increased. Wherein, the positive control groups 1 and 2 and the low, medium and high three-dose sipunculus administration groups have significant difference (P is less than 0.01) in TG content compared with the negative control group, and the medium and high dose groups have lower TG content than the positive control groups 1 and 2; (2) the TC content of the positive control groups 1 and 2 and the low, medium and high dose groups is very significantly different (P is less than 0.01) compared with that of the negative control group, but no significant difference exists between the low and medium dose groups (P is more than 0.05); (3) the LDL-C content of the positive control group 1, the medium-dose sipunculus nudus group and the high-dose sipunculus nudus group is significantly different (P is less than 0.01) than that of the negative control group, the LDL-C content of the positive control group 2 and that of the low-dose sipunculus nudus group are significantly different (P is less than 0.05) than that of the negative control group, and the medium-dose group and the high-dose group are better than that of the positive control group 2, but have no significant difference (P is more than 0.05) between the medium-dose group and the high-dose group; (4) the HDL-C content of the negative control group is the lowest, the HDL-C content of the positive control groups 1 and 2 and the HDL-C content of the medium dose group are respectively remarkably different from that of the negative control group (P is less than 0.01), and the HDL-C content of the low and high dose group is respectively remarkably different from that of the negative control group (P is less than 0.05). The results show that the content of TG, TC and LDL-C in the serum of the hyperlipidemic mouse can be reduced and the content of HDL-C in the serum of the mouse can be increased by the administration of different doses of the sipunculus nudus powder, which indicates that the sipunculus nudus powder has good auxiliary hypolipidemic effect on experimental hyperlipidemic mice.
The arteriosclerosis index AI can be calculated from the formula AI ═ (TC-HDL-C)/HDL-C. The positive control groups 1 and 2 and the low, medium and high dose sipunculus nudus groups can obviously reduce the AI index, and have obvious difference (P is less than 0.05) compared with the negative control group, but have no obvious difference (P is more than 0.05) among the three dose groups, which indicates that the sipunculus nudus powder can have the function of preventing atherosclerosis, thereby indicating that the sipunculus nudus has the function of reducing blood fat, and reducing the risk of atherosclerosis and coronary heart disease caused by hyperlipidemia.
2.3 Effect on mouse liver
Table 2 mouse liver weight, body weight and liver coefficient (n-10,
)
table 2 is the effect of phascolosoma esculenta on mouse liver: after the eyeball of a mouse is picked and blood is taken, cervical vertebra is dislocated and killed, the whole liver is picked, the surface layer blood silk is rinsed by precooled normal saline, the excessive tissue is removed and then is sucked by filter paper, the weight of the mouse is weighed, and the liver coefficient is calculated according to the formula (liver coefficient (%) -liver weight (g)/weight (g) multiplied by 100). Compared with the normal group, the liver coefficient of the negative control group is increased and is 1.6 times of that of the normal group, the liver coefficient is reduced after the administration, and the liver coefficient is reduced along with the increase of the administration dosage of the sipunculus nudus.
The appearance of the liver before and after administration is shown in FIG. 3, from which it can be seen that the liver of the normal group mice was dark red, smooth in surface and soft in texture, while the liver of the negative control group mice was swollen, light in color, had particles on the surface, had yellow fat droplets exuded and had brittle texture. After administration, the liver of each group is darker than that of the negative control group, the surface of the liver is free of particles and is smoother, and the color of the positive control group 1 is darker than that of the positive control group 2. The liver conditions of the low, medium and high-dose sipunculid groups are improved compared with the negative control group, which shows that the sipunculid powder has a certain protection effect on the liver of the experimental hyperlipidemic mouse.
And (3) detecting the content of TG and TC in the liver tissue of the mouse: adding a proper amount of liver tissue into PBS buffer solution according to the mass-to-volume ratio of 1:9, grinding by a tissue grinder, centrifuging at 3500rpm for 10min, taking supernatant, determining the content of the liver tissue protein by a BCA method, establishing a regression equation by using standard protein light absorption values with different concentrations, wherein the protein concentration of 0.1-0.5mg/ml and the light absorption value of 562nm have a good linear relationship, and drawing (as shown in figure 4) by using the light absorption value as an ordinate and the standard protein concentration as an abscissa to obtain a standard curve, wherein the regression equation is that y is 0.58x +0.0769, R is R2＝0.9952。
Table 3 mouse liver TG, TC content (n-10,
)
note: (p <0.01 indicates a significant difference from the negative control group, and p <0.05 indicates a significant difference from the negative control group)
Table 3 is the effect of phascolosoma esculenta on TG, TC content in mouse liver: compared with the normal group, the content of TG and TC in the liver tissue of the negative control group is obviously increased, and the content is reduced after administration. Wherein (1) the positive control group 2, the medium-dose sipunculus nudus group and the high-dose sipunculus nudus group have extremely significant difference (P < 0.01) in TG content compared with the negative control group, but no significant difference (P >0.05) exists among the three groups; (2) the TC content of the positive control group 2, the medium-dose sipunculus nudus group and the high-dose sipunculus nudus group is very significant difference (P < 0.01) compared with that of the negative control group, but the TC content of the three groups is not significant difference (P > 0.05). The sipunculid beetle powder has certain effect of reducing the content of TG and TC in liver tissues of experimental hyperlipidemic mice.
The above results show that: compared with a negative control group which is given with physiological saline, the low, medium and high doses of the phascolosoma esculenta powder can reduce the serum Total Cholesterol (TC), Triglyceride (TG) and low-density lipoprotein cholesterol (LDL-C) content of experimental hyperlipidemic mice, increase the serum high-density lipoprotein cholesterol (HDL-C) content, reduce the Arteriosclerosis Index (AI) and reduce the TG and TC content of liver tissues, and has a certain protective effect on the liver.
The above examples show that the phascolosoma esculenta powder has a good blood fat reducing effect on hyperlipidemic mice, has a certain protection effect on the liver, has positive significance for preventing and treating atherosclerosis and arterial thrombosis and ischemic cardiovascular and cerebrovascular diseases caused by atherosclerosis, can be applied to blood fat reducing drugs and health care products, and has a wide application prospect.
Although specific embodiments of the invention have been described above, it will be understood by those skilled in the art that the specific embodiments of the invention described are illustrative only and are not limiting to the scope of the invention, and that equivalent modifications and variations can be made by those skilled in the art without departing from the spirit of the invention, which is to be covered by the appended claims.
Claims (1)
1. The application of the phascolosoma esculenta in preparing the hypolipidemic drug and the health-care product is characterized in that: the Phascolosoma esculenta is processed by the following steps:
1. raw materials: selecting natural high-quality phascolosoma esculenta;
2. cleaning: washing away silt by using clear water, and then washing by using salt water for multiple times;
3. air drying: sun drying and natural air drying outdoors in daytime;
4. drying: drying at 28 deg.C in a drying oven at night until constant weight;
5. grinding: intermittently grinding by a dry powder grinder;
6. grading and screening: sequentially sieving with 20 mesh, 40 mesh and 60 mesh sieves to obtain Phascolosoma esculenta dry powder;
the prepared phascolosoma esculenta powder is applied to blood fat reducing medicines and blood fat reducing health care products.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2016108961010 | 2016-10-14 | ||
| CN201610896101 | 2016-10-14 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106581080A CN106581080A (en) | 2017-04-26 |
| CN106581080B true CN106581080B (en) | 2020-02-07 |
Family
ID=58594712
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611088037.XA Active CN106581080B (en) | 2016-10-14 | 2016-12-01 | Application of Phascolosoma esculenta in preparation of blood lipid lowering medicine and health product |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106581080B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107163155B (en) * | 2017-05-09 | 2020-03-24 | 华侨大学 | Preparation method and application of phascolosoma esculenta polysaccharide |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101210261A (en) * | 2006-12-29 | 2008-07-02 | 宁波大学 | Method for preparing sipunculid polypeptide and application thereof |
| CN103333875A (en) * | 2013-05-09 | 2013-10-02 | 许瑞安 | Marine phasolosma esculenta fibrinolytic enzyme, preparation method and applications thereof |
| CN104938684A (en) * | 2014-03-31 | 2015-09-30 | 湖南省怡清源茶业有限公司 | Tea for assisting reduction of blood lipid and preparation method thereof |
-
2016
- 2016-12-01 CN CN201611088037.XA patent/CN106581080B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101210261A (en) * | 2006-12-29 | 2008-07-02 | 宁波大学 | Method for preparing sipunculid polypeptide and application thereof |
| CN103333875A (en) * | 2013-05-09 | 2013-10-02 | 许瑞安 | Marine phasolosma esculenta fibrinolytic enzyme, preparation method and applications thereof |
| CN104938684A (en) * | 2014-03-31 | 2015-09-30 | 湖南省怡清源茶业有限公司 | Tea for assisting reduction of blood lipid and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN106581080A (en) | 2017-04-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101040711A (en) | The application of Suaeda plant extraction in the food having health-care and weight-losing functions | |
| CN106107461A (en) | A kind of hyperglycemia population that is suitable for eats series food and preparation method thereof | |
| CN105661515B (en) | A kind of ferment lozenge for preventing three high diseases and preparation method thereof | |
| CN101297704B (en) | Health care food for protecting liver and manufacturing method thereof | |
| CN106581080B (en) | Application of Phascolosoma esculenta in preparation of blood lipid lowering medicine and health product | |
| CN104667197A (en) | Composition for strengthening immunity and preparation method and application of composition | |
| CN1864530A (en) | A refined health food of high and cold mountain area crop and processing technology thereof | |
| CN106692361A (en) | Fagopyrum tataricum composition, preparation method thereof, preparations and application | |
| CN103432169A (en) | Ginseng colla corii asini bead processed drug and processing method thereof | |
| CN101912407B (en) | Weight-reducing and lipid-lowering composition | |
| CN107163155B (en) | Preparation method and application of phascolosoma esculenta polysaccharide | |
| CN1376397A (en) | Ganoderma tea and its preparing process | |
| CN104382038B (en) | A kind of soft capsule for improving immunity | |
| CN1293963A (en) | Health-care microalga food and its preparing process | |
| CN1095241A (en) | Sealwort beverage and manufacture method thereof | |
| CN1686519A (en) | Medicinal composition for preventing alcoholic liver damage | |
| CN107961293A (en) | A kind of sea-buckthorn tomato piece and preparation method thereof | |
| CN113729153A (en) | Formula and preparation method of plant selenium earthworm and tempeh tablet | |
| CN111480846A (en) | Health-care product for assisting in reducing blood fat and improving immunity | |
| CN1173640C (en) | Nutritive health-care food | |
| CN107411085A (en) | It is a kind of to adjust health-care food composition of blood fat and preparation method thereof | |
| CN1067270C (en) | Nutritious health care medicine | |
| CN109924413A (en) | A kind of jerusalem artichoke wheat composite powder and preparation method thereof | |
| CN102793891A (en) | Traditional Chinese medicine composition having functions of reducing blood fat and resisting hyperuricemia | |
| CN107412283A (en) | A kind of three high drop composition containing Agricus blazei extract and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |